PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 17, 2026IJU Case Reports0 citationsOpen Access

A Case of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Achieving Pathologic Complete Response Following Combination Therapy With Lenvatinib and Pembrolizumab

View Full Paper
HTHiroki TakayamaTSTakeshi SanoKHKento Hirao

Key Points

  • To evaluate the impact of neoadjuvant lenvatinib and pembrolizumab on renal cell carcinoma with inferior vena cava tumor thrombus.
  • Presented case of an 80-year-old man with clear cell renal cell carcinoma.
  • Administered neoadjuvant therapy with lenvatinib and pembrolizumab.
  • Performed robot-assisted radical nephrectomy and lymphadenectomy, converting to open surgery due to complications.
  • Conducted pathological examination to assess response.
  • Primary renal tumor showed marked shrinkage after treatment.
  • Inferior vena cava tumor thrombus had slight size reduction.
  • Pathological examination showed no residual viable cancer cells.
  • Patient remained free of recurrence for 1.5 years postoperatively.

Abstract

ABSTRACT Introduction The efficacy of neoadjuvant lenvatinib plus pembrolizumab for clear cell renal cell carcinoma with inferior vena cava tumor thrombus remains unclear. Case Presentation An 80‐year‐old man was diagnosed with clear cell renal cell carcinoma and tumor thrombus extending into the inferior vena cava. Following neoadjuvant lenvatinib plus pembrolizumab, the primary renal tumor shrank markedly, whereas the inferior vena cava tumor thrombus demonstrated only a slight reduction in size. Robot‐assisted radical nephrectomy and lymphadenectomy were performed; however, conversion to open surgery was required because of an inferior vena cava laceration. Pathological examination revealed no residual viable cancer cells. The patient has remained free of recurrence for 1.5 years postoperatively. Conclusion In this case, a pathological complete response was achieved following combination therapy of lenvatinib with pembrolizumab.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Takayama et al. (2026) studied this question.

synapsesocial.com/papers/69b8f13ddeb47d591b8c6301https://doi.org/10.1002/iju5.70165
Ask AI
Helpful
Bookmark
Share
View Full Paper